Newly Published Data Demonstrates Amifostine Delayed The Onset Of Acute Esophagitis For Small Cell Lung Cancer Patients
Cumberland markets branded amifostine in the U.S territory under the name Ethyol® on behalf of
Concurrent chemoradiotherapy, delivered every three weeks in conjunction with radiotherapy, is recognized as a standard treatment option in patients with stage 3 small cell lung carcinoma. Acute esophageal inflammation has been described as a dose-limiting effect and is observed in ~25% of patients undergoing such treatment. Studies have reported a relationship between the volume of the esophagus irradiated and the likelihood of an acute injury. Series have reported volumes of esophagus irradiated as most reflective of acute symptoms.
The study, led by Ariel E Pollock M.D,
The study investigators concluded, based on their observations and objective measurements, that subcutaneous amifostine may postpone the onset of acute esophagitis in a subset of patients with small cell lung carcinoma receiving concurrent chemoradiotherapy.
About Ethyol® (amifostine)
Ethyol is indicated to reduce the cumulative renal toxicity associated with repeated administration of cisplatin in patients with advanced ovarian cancer. It is indicated to reduce the incidence of moderate to severe xerostomia in patients undergoing post-operative radiation treatment for head and neck cancer, where the radiation port includes a substantial portion of the parotid glands. Xerostomia, or diminished saliva production, can lead to difficulties eating, speaking, and swallowing. Ethyol is contraindicated in patients with known hypersensitivity to aminothiol compounds.
For full prescribing and important safety information, please visit www.ethyol.com.
For more information, please visit www.cumberlandpharma.com.
For more information, please visit www.clinigengroup.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/newly-published-data-demonstrates-amifostine-delayed-the-onset-of-acute-esophagitis-for-small-cell-lung-cancer-patients-300720169.html
Media Contact, Jeff Bradford, the Bradford Group, (615) 515-4880; Investor Contact, Erin Smith, Corporate Relations, (615) 255-0068; Clinigen Group plc, Shaun Chilton, Group Chief Executive Officer, Matt Parrish, Head of Investor Relations, +44 (0) 1283 495010